7th Dec 2015 07:54
LONDON (Alliance News) - Allergy Therapeutics PLC said Monday that it has begun enrolment of its US Phase II study of its grass allergic rhinitis vaccine GrassMATAMPL, enrolling its first ten patients.
The study is expects to read out in the second quarter of 2016, and precedes a phase III study for US approval.
"The US clinical development programme for our ultra-short course, aluminium-free allergy vaccine for grass remains on track. We continue to expect to file for US approval at the end of 2018," said Chief Executive Officer Manuel Llobet in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.